Semaglutide superior to dulaglutide on glucose control and weight loss in people with type 2 diabetes in SUSTAIN 7 - Seite 2
"The superior glucose control and weight loss achieved with semaglutide compared to dulaglutide in this trial reinforces the unprecedented results observed in the entire SUSTAIN programme" said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. "We are excited about the potential of semaglutide to set a new standard for treatment of type 2 diabetes".
About semaglutide
Semaglutide is a once-weekly analogue of human glucagon-like peptide-1 (GLP-1) that stimulates insulin and suppresses glucagon secretion in a glucose-dependent manner, while decreasing appetite and
food intake. Once-weekly semaglutide is currently under review by seven regulatory agencies, including the US Food and Drug Administration, the European Medicines Agency and the Japanese
Pharmaceuticals and Medical Devices Agency.
SUSTAIN 7
SUSTAIN 7 is a phase 3b, 40-week, efficacy and safety trial of 0.5 mg semaglutide vs 0.75 mg dulaglutide and 1.0 mg semaglutide vs 1.5 mg dulaglutide, both once-weekly, as add-on to metformin in
1,201 people with type 2 diabetes. The primary outcome measure was change in HbA1c from baseline after 40 weeks of
treatment with semaglutide compared to dulaglutide.
About the SUSTAIN clinical programme
SUSTAIN (Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes) is a clinical trial programme for semaglutide, administered once weekly, that comprises seven phase 3 global clinical
trials, including a cardiovascular outcomes trial, involving more than 8,000 adults with type 2 diabetes.
Further information
Media: | ||
Katrine Sperling | +45 3079 6718 | krsp@novonordisk.com |
Ken Inchausti (US) | +1 609 786 8316 | kiau@novonordisk.com |
Investors: | ||
Peter Hugreffe Ankersen | +45 3075 9085 | phak@novonordisk.com |
Hanna Ögren | +45 3079 8519 | haoe@novonordisk.com |
Anders Mikkelsen | +45 3079 4461 | armk@novonordisk.com |
Christina Jensen | +45 3079 3009 | cnje@novonordisk.com |
Kasper Veje (US) | +1 609 235 8567 | kpvj@novonordisk.com |
Lesen Sie auch
Company announcement No 65 / 2017